{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:58:34Z","timestamp":1784307514819,"version":"3.55.0"},"reference-count":19,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2,6]]},"abstract":"<jats:p>Cutaneous leishmaniasis is clinically widespread but lacks treatments that are effective and well tolerated. Because all present drugs have been grandfathered into clinical use, there are no examples of a pre-clinical product evaluation scheme that lead to new candidates for formal development. To provide oral agents for development targeting cutaneous leishmaniasis, we have implemented a discovery scheme that incorporates <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> testing of efficacy, toxicity, and pharmacokinetics\/metabolism. Particular emphasis is placed on <jats:italic>in vivo<\/jats:italic> testing, progression from higher-throughput models to those with most clinical relevance, and efficient use of resources.<\/jats:p>","DOI":"10.4269\/ajtmh.11-0812","type":"journal-article","created":{"date-parts":[[2013,2,6]],"date-time":"2013-02-06T16:20:34Z","timestamp":1360167634000},"page":"216-221","source":"Crossref","is-referenced-by-count":31,"title":["Drug Discovery Algorithm for Cutaneous Leishmaniasis"],"prefix":"10.4269","volume":"88","author":[{"given":"Max","family":"Grogl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Lazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Sharlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Sciotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2795","reference":[{"key":"R1","series-title":"Trans R Soc Trop Med Hyg","first-page":"239","article-title":"The increase in risk factors for leishmaniasis worldwide","volume":"95","author":"Desjeux","year":"2001"},{"key":"R2","series-title":"World Health Organ Tech Rep Ser","first-page":"1","article-title":"Control of the leishmaniases","volume":"949","author":"World Health Organization","year":"2010"},{"key":"R3","series-title":"Clin Infect Dis","first-page":"409","article-title":"Designing and reporting clinical trials on treatments for cutaneous leishmaniasis","volume":"51","author":"Gonzalez","year":"2010"},{"key":"R4","series-title":"Mol Interv","first-page":"72","article-title":"Anti-leishmanial drug discovery: rising to the challenges of a highly neglected disease","volume":"10","author":"Sharlow","year":"2010"},{"key":"R5","series-title":"PLoS Negl Trop Dis","first-page":"e432","article-title":"WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a Phase 2, randomized, double blind, placebo controlled study","volume":"3","author":"Ben Salah","year":"2009"},{"key":"R6","series-title":"PLoS Negl Trop Dis","first-page":"e540","article-title":"Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen","volume":"3","author":"Sharlow","year":"2009"},{"key":"R7","series-title":"Nat Protoc","first-page":"1350","article-title":"Development, validation and implementation of immobilized metal affinity for phosphochemicals (IMAP)-based high-throughput screening assays for low-molecular-weight compound libraries","volume":"3","author":"Sharlow","year":"2008"},{"key":"R8","series-title":"PLoS Negl Trop Dis","first-page":"e1253","article-title":"A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit","volume":"5","author":"De Muylder","year":"2011"},{"key":"R9","series-title":"Antimicrob Agents Chemother","first-page":"1182","article-title":"Identification of new antileishmanial leads from hits obtained by high-throughput screening","volume":"56","author":"Zhu","year":"2012"},{"key":"R10","series-title":"Trends Parasitol","first-page":"383","article-title":"The role of host genetics in leishmaniasis","volume":"25","author":"Sakthianandeswaren","year":"2009"},{"key":"R11","series-title":"J Parasitol","first-page":"780","article-title":"Development of Leishmania (Vianna) panamensis lesions and relationship of numbers of amastigotes to lesion areas on antimony-treated and untreated hamsters","volume":"77","author":"Hanson","year":"1991"},{"key":"R12","series-title":"Mutat Res","first-page":"29","article-title":"The Ames Salmonella\/M microsome mutagenicity assay","volume":"455","author":"Mortelmans","year":"2000"},{"key":"R13","series-title":"Mutat Res","first-page":"81","article-title":"The in vitro micronucleus technique","volume":"455","author":"Fenech","year":"2000"},{"key":"R14","series-title":"Trends Pharmacol Sci","first-page":"119","article-title":"Predicting drug-hERG channel interactions that cause acquired long QT syndrome","volume":"26","author":"Sanguinetti","year":"2005"},{"key":"R15","series-title":"Antimicrob Agents Chemother","first-page":"5108","article-title":"Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis","volume":"53","author":"Serrano-Mart\u00edn","year":"2009"},{"key":"R16","series-title":"Exp Parasitol","first-page":"315","article-title":"Leishmania (Leishmania) amazonensis infection: muscular involvement in BALB\/c and C3H.HeN mice","volume":"124","author":"Silva-Almeida","year":"2010"},{"key":"R17","series-title":"Eur J Immunol","first-page":"2816","article-title":"Murine model of chronic L. (Viannia) panamensis infection: role of IL-13 in disease","volume":"40","author":"Castilho","year":"2010"},{"key":"R18","series-title":"Am J Trop Med Hyg","first-page":"579","article-title":"Cross-protection against Leishmania donovani but not L. braziliensis caused by vaccination with L. major soluble promastigote exogenous antigens in BALB\/C mice","volume":"76","author":"Tonui","year":"2007"},{"key":"R19","series-title":"Mem Inst Oswaldo Cruz","first-page":"358","article-title":"In vitro and in vivo activity of meglumine antimoniate produced at Farmanguinhos-Fiocruz, Brazil, against Leishmania (Leishmania) amazonensis, L. (L.) chagasi and L. (Viannia) braziliensis","volume":"103","author":"Morais-Teixeira","year":"2008"}],"container-title":["The American Society of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/88\/2\/article-p216.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/88\/2\/article-p216.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/88\/2\/article-p216.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T18:45:47Z","timestamp":1723056347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/88\/2\/article-p216.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,6]]},"references-count":19,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.11-0812","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,6]]}}}